Pernix Therapeutics to Present at the 12th Annual Needham Healthcare Conference

  Pernix Therapeutics to Present at the 12th Annual Needham Healthcare

Needham Healthcare Conference 2013

Business Wire

THE WOODLANDS, Texas -- April 23, 2013

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced that Cooper Collins, President and Chief Executive
Officer, will present at the 12^th Annual Needham Healthcare Conference on
Tuesday, April 30, 2013 at 12:10 p.m. EST. The conference will be held at
Westin Grand Central Hotel in New York, NY.

The presentation will be broadcast live over the Internet and can be accessed
on the Company’s website,, under “Webcasts and Presentation”
on the investor relations section. The audio-recording of the presentation
will be archived on the Company’s website for approximately 30 days following
the conclusion of the presentation.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded
products, including the recently acquired Hawthorn Pharmaceuticals’ product
line. The Company’s branded products for the pediatrics market include CEDAX®,
an antibiotic for middle ear infections, NATROBA™, a topical treatment for
head lice marketed under an exclusive co-promotion agreement with ParaPRO,
LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX®
and PEDIATEX®). The Company’s branded products for gastroenterology include
OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal ulcer
disease, and REZYST™, a probiotic blend to promote dietary management. The
Company also markets the branded product, SILENOR®, for the treatment of
insomnia. The Company promotes its branded pediatric and gastroenterology
products through its sales force. Pernix markets its generic products through
its wholly-owned subsidiaries, Cypress Pharmaceutical and Macoven
Pharmaceuticals. The Company’s wholly-owned subsidiary, Pernix Manufacturing,
manufactures and packages products for the pharmaceutical industry in a wide
range of dosage-forms.

Additional information about Pernix is available on the Company’s website
located at


Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, 800-793-2145 ext. 3002
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.